BioCryst Pharmaceuticals

Update in progress

BCRX (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic

BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on medicines for hereditary angioedema and other rare diseases. It markets RAPIVAB/RAPIACTA/PERAMIFLU (intravenous peramivir) for influenza and ORLADEYO (berotralstat) for HAE. It is developing BCX17725 for netherton syndrome, Avoralstat for diabetic macular edema, Navenibart for HAE, STAR-0310 for atopic dermatitis, and KLK5 inhibitors in early trials. Founded 1986; based in Durham, NC.

Company score

Sentiment: 0.51; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.03; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.43; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.21; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.18; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.35; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive